Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis
Journal of Experimental Medicine · 2025
DOI: 10.1084/jem.20250153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Li Zhou und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology & State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences, Chinese Academy…. Hauptthemen laut MEDLINE: Janus Kinase 2, Receptors, Aryl Hydrocarbon, Thrombocythemia, Essential, Thrombosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
JAK2V617F causes >50% essential thrombocythemia (ET) and >90% polycythemia vera (PV). How such a single mutation causes distinct disorders remains a long-standing enigma. Here, we show that heterozygous JAK2V617F activates the transcription factor aryl hydrocarbon receptor (AhR), which biases MEP differentiation toward megakaryocytes in ET patients. In contrast, most PV patients’ JAK2V617F exhibits a homozygous mutation that does not activate AhR. We found that JAK2V617F forms a heterodimer with JAK2 to recruit and activate STAT1, thereby inducing AhR activation and driving ET pathogenesis. However, JAK2 forms V617F homodimers in PV patients, which activate STAT5 and drive PV development. In addition to increasing platelet number, activated AhR may enhance platelet activity via the COX2–TXA2 axis. Importantly, targeting AhR inhibits thrombocytosis in JAK2V617F ET humanized mice. These findings not only elucidate the molecular mechanism of JAK2V617F ET but also provide a potential strategy for its treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology & State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College, Beijing, C…
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, Chi…
- The Department of Obstetrics, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China.
- Department of Biochemistry and Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
ORCID-Profile: Li Zhou, Dongxiao Wu, Yabo Zhou, Dianheng Wang, Zhuo-Yu An, Peng Zhao, Shaoyang Lai, Zhenfeng Wang, Nannan Zhou, Jie Chen, Jiadi Lv, Xiaohui Zhang, Bo Huang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
Zitieren
APA
Zhou, L., Wu, D., Zhou, Y., Wang, D., An, Z. Y., Zhao, P., Lai, S., Wang, Z., Zhou, N., Chen, J., Lv, J., Zhang, X., & Huang, B. (2025). Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20250153
Vancouver
Zhou L, Wu D, Zhou Y, Wang D, An ZY, Zhao P, et al. Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis. Journal of Experimental Medicine. 2025. doi:10.1084/jem.20250153
BibTeX
@article{Zhou2025,
author = {Zhou, Li and Wu, Dongxiao and Zhou, Yabo and Wang, Dianheng and An, Zhuo-Yu and Zhao, Peng and Lai, Shaoyang and Wang, Zhenfeng and Zhou, Nannan and Chen, Jie and Lv, Jiadi and Zhang, Xiaohui and Huang, Bo},
title = {Heterozygous human JAK2V617F activates AhR to drive essential thrombocythemia and promote thrombosis},
journal = {Journal of Experimental Medicine},
year = {2025},
doi = {10.1084/jem.20250153}
}
EUVIMED